Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
450 participants
INTERVENTIONAL
2026-02-01
2041-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of the project is to continue identifying genetic factors, and also to understand the biological mechanisms involved in the emergence of autistic symptoms.
Identifying biological pathways is an essential step in developing new therapeutic strategies. In addition, one of the major challenges of this study is to better understand the phenotype/genotype relationships in ASD. This requires in-depth knowledge of the phenotypic characteristics of ASD participants and their families, as well as neurotypical populations. This study combines the scientific expertise of researchers specializing in molecular biology, phenotypic exploration (clinical, cognitive, MRI, EEG, biochemistry, immunology), and the use of pre-therapeutic cellular models (iPSCs, neural precursors, organoids).
The objectif of this work is the identification of numerous genes associated with ASD and involved in synaptic formation and regulation: NLGN3-4, SHANK1 and SHANK3, CNTN-6, and CNTNAP4. This work was combined with in-depth phenotypic explorations of ASD participants and their relatives. It has made it possible to clarify the neuroanatomical characteristics of ASD participants and their genetic substrate, as well as the underlying cognitive processes.
All of this work opens up new prospects for identifying new therapeutic targets using preclinical cell models (IPS, neural progenitors, organoids) developed in particular by I-Stem and Human Technopole.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Aim 2 : To study the cellular mechanisms affected by the presence of abnormalities identified in participants with ASD. The use of pluripotent cells derived into neurons or organoids is a major tool for understanding the pathophysiology of cell development and pathways in autism. These derived neurons are an indispensable proxy for the biological understanding of ASD.
* Aim 3 : To identify new therapeutic approaches , by using pluripotent cells and organoids to perform high-throughput screening of pharmacological compounds.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probands with Autism Spectrum Disorder, (N=200).
All subjects included in this study will be drawn from the population of subjects already included in the studies entitled 'Genes and Autism' promoted by Inserm (NCT02628808/C07-33 and NCT04727489/C16-89).
Patients are diagnosis ASD according to DSM-V criteria and carry genetic variations known to be associated with autism (whether rare or common).
Blood Sample : isolation of peripheral blood mononuclear cells (PBMCs)
Participation in this study requires a single visit per participant. This study only requires a blood sample (5 to 30 minutes) to be taken at the CIC at Robert-Debré Hospital, Paris 19th arrondissement.
This blood sample will enable the isolation of peripheral blood mononuclear cells (PBMCs). HIV, HCV and HBV serology will also be performed.
Controls without Autism Spectrum Disorder
At least, 24 months old (N=150) All subjects included in this study will be drawn from the population of subjects already included in the studies entitled 'Genes and Autism' promoted by Inserm (NCT02628808/C07-33 and NCT04727489/C16-89).
Blood Sample : isolation of peripheral blood mononuclear cells (PBMCs)
Participation in this study requires a single visit per participant. This study only requires a blood sample (5 to 30 minutes) to be taken at the CIC at Robert-Debré Hospital, Paris 19th arrondissement.
This blood sample will enable the isolation of peripheral blood mononuclear cells (PBMCs). HIV, HCV and HBV serology will also be performed.
Relatives of the probands with ASD
Adult relatives of controls with ASD (N=100) All subjects included in this study will be drawn from the population of subjects already included in the studies entitled 'Genes and Autism' promoted by Inserm (NCT02628808/C07-33 and NCT04727489/C16-89).
Blood Sample : isolation of peripheral blood mononuclear cells (PBMCs)
Participation in this study requires a single visit per participant. This study only requires a blood sample (5 to 30 minutes) to be taken at the CIC at Robert-Debré Hospital, Paris 19th arrondissement.
This blood sample will enable the isolation of peripheral blood mononuclear cells (PBMCs). HIV, HCV and HBV serology will also be performed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood Sample : isolation of peripheral blood mononuclear cells (PBMCs)
Participation in this study requires a single visit per participant. This study only requires a blood sample (5 to 30 minutes) to be taken at the CIC at Robert-Debré Hospital, Paris 19th arrondissement.
This blood sample will enable the isolation of peripheral blood mononuclear cells (PBMCs). HIV, HCV and HBV serology will also be performed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 1\) Be Included in the "Genes and Autism" protocol (C07-33 or C16-89).
* 2\) Affiliated to the social insurance, Universal Health Coverage or any equivalent system.
● Participants with ASD.
* 1\) Autistic patients must meet the diagnostic criteria of DSM-IV \[American Psychiatric Association, 1994\] and the criteria of ADI-R (Autism Diagnostic Interview-Revised, Lord et al., 1994) and ADOS for autism.
..Or.. Patients with Asperger's syndrome must meet the DSM-IV criteria as well as the ASDI criteria for Asperger's syndrome (Asperger Syndrome Diagnostic Interview, Gillberg et al., 2001) and the ADOS for autism spectrum disorders.
..Or.. Patients with ASD must meet diagnostic criteria of DSM-IV and ADOS criteria for autism spectrum disorders
* 2\) Be at least 2 years old, with no upper age limit
* 3\) Somatic state compatible with blood test
● Adult controls and adult relatives of controls
* 1\) Be between 18 and 65 years old
* 2\) Somatic and intellectual state compatible with blood test
● Controls with mental retardation
* 1\) Minimum age of 2 yearsIQ \< 70Child controls
* 2\) Minimum age of 2 years
● Probands with ASD
* 1\) Meet the diagnostic criteria for ASD of the of DSM-5 \[American Psychiatric Association, 2012\]. The diagnosis will be based on a consensus between the clinical expertise of expert clinicians, the scores of the Autism Diagnostic Interview-Revised (ADI-R) (Lord et al, 2003) and those of the Autism Diagnosis Observational Scale (ADOS-2) (Lord et al, 1994)
* 2\) Be at least 24 months old with no upper age limit
* 3\) Somatic state compatible with a blood test
* 4\) Affiliation to the Social Insurance
* 5\) Signature of informed consent by the applicant or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship
● Controls wihout ASD
* 1\) At least 24 months old
* 2\) Somatic and Intellectual state compatible with a blood test
* 3\) Affiliation in the Social Insurance
* 4\) Signature of informed consent by the subject or by holders of parental authority if the subject is a minor, or by the guardian if the subject is under guardianship
● Relatives of the probands with ASD or of controls without ASD
* 1\) At least 24 months old
* 2\) Somatic and intellectual state compatible with blood test
* 3\) Affiliation to the Social Insurance
* 4\) Signature of informed consent by the subject or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship
Exclusion Criteria
* 1\) Refusal to have a blood test
* 2\) Medical illness (including psychiatric disorder) not yet fully stabilised and making participation in the study impossible
* 3\) Person subject to a mesure of lagal protection
* 4\) Known serology : VIH+ or VBH+ or VCH+
* 1\) For all participants : Severe Intelectual Deficiency (IQ,35 or developmental age \<18 months)
* 2\) Controls : Neurological or psychiatric history other than mental retardation
o Psychiatric history, except for mental retardation, assessed using the DIGS (Diagnostic Interview for Genetic Studies, Nurnberger et al., 1994) for adults or the Kiddie-SADS (Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children, Orvaschel et al., 1982)
o History of epileptic episodes
o Immunosuppressive treatment or known immunoinflammatory disease
* 1\) Probands with Autism Spectrum Disorder
o Severe intellectual disability (IQ\<35 or developmental age \<18 months)
* 2\) Controls (neurotypical development)
o Identified intellectual disorder or cognitive developmental disorder
* Personal psychiatric history of schizophrenia, bipolar disorder, substance use disorders (except tobacco), recurrent depression (\>2 episodes, lifetime), severe unstabilized anxiety disorder
* History of epilepsy episodes or severe neurological disease
* 3\) Relatives of the TSA applicants or controls
* Medical condition (psychiatric or somatic) not compatible with inclusion
2 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
APHP
OTHER
Institut Pasteur
INDUSTRY
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Pr Bourgeron, Professor
Role: STUDY_DIRECTOR
Institut Pasteur
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C22-14
Identifier Type: -
Identifier Source: org_study_id